{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-056731","form_type":"8-K","ticker":"CBUS","cik":"0001705843","company_name":"Cibus, Inc.","filed_at":"2026-08-13T20:14:58+00:00","discovered_at":"2026-08-13T20:16:00.284804+00:00","generated_at":"2026-08-13T20:16:15.154465+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cibus Q2 net loss $22.1M, cash $20.4M, EU gene-editing rule favorable, Interoc expands to 5 Rice traits","bullets":["Net loss $22.1M vs $26.6M YoY; EPS -$0.29 vs -$0.61.","Cash $20.4M; expects to fund into early Q1 2027; quarterly net cash usage down 19% QoQ, 31% YoY.","EU approved gene-edited crops as conventional (June 2026); supports Rice and other programs.","Interoc amended LOI to expand from 2 to 5 Rice traits; potential 2028 launch.","Craig Wichner appointed CEO effective June 8, 2026; Peter Beetham remains President/COO."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-056731","json":"https://secwatch.observer/filing/0001628280-26-056731.json","markdown":"https://secwatch.observer/filing/0001628280-26-056731.md","text":"https://secwatch.observer/filing/0001628280-26-056731.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1705843/000162828026056731/0001628280-26-056731-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1705843/000162828026056731/cbus-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:16:15.154465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}